| |
|
Product Name:
|
UgMP 30
|
|
Ownership statement:
|
This reagent is the property of the U.S. Government.
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Virus Classification: Togaviridae, Alphavirus Species: O’nyong-nyong virus Strain/Isolate: UgMP 30
|
|
Additional Information:
|
ONNV is a single-stranded RNA virus belonging to the group of mosquito-borne viruses including Chikungunya virus, Mayaro virus, River Ross virus and Sindbis virus known to cause arthritis in humans.2 ONNV was first isolated during a major epidemic in Uganda in 1959, which later spread to countries in south-eastern Africa. ONNV is transmitted by anopheline mosquitoes with humans as amplification host during epidemics.3,4 Clinical manifestations of infection with ONNV include an acute febrile episode with skin rash, lymphadenopathy, joint pains followed by polyarthralgia and myalgia that can be severe and long lasting.3,5
|
|
Material Provided:
|
Each vial contains approximately 1 mL of cell lysate and supernatant from Chlorocebus aethiops kidney epithelial cells infected with ONNV, UgMP 30.
Note: If homogeneity is required for your intended use, please purify prior to initiating work.
|
|
Packing/Storage:
|
NR-51661 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Host: Chlorocebus aethiops kidney epithelial cells (Vero E6; ATCC® CRL-1586™)Growth Medium: Dulbecco’s Minimum Essential Medium containing Earle’s Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1.5 g/L of sodium bicarbonate supplemented with 2% fetal bovine serum, or equivalentInfection: Cells should be 90% to 95% confluentIncubation: 2 to 4 days at 37°C and 5% CO2Cytopathic Effect: Cell rounding and sloughing
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Russell, B.J., Personal Communication.
2. Lwande, O. W., et al. “Global Emergence of Alphaviruses that Cause Arthritis in Humans.” Infect. Ecol. Epidemiol. 18 (2015): 29853. PubMed: 26689654.
3. Nyaruaba, R., et al. “Arboviruses in the East African Community Partner States: A Review of Medically Important Mosquito-Borne Arboviruses.” Pathog. Glob. Health 113 (2019): 209-228. PubMed: 31664886.
4. Pezzi, L., et al. “GloPID-R Report on Chikungunya, O’nyong-nyong and Mayaro Virus, Part I: Biological Diagnostics.” Antiviral Res. 166 (2019): 66-81. PubMed: 30905821.5. Gall, B., et al. “Emerging Alphaviruses are Sensitive to Cellular States Induced by a Novel Small-Molecule Agonist of the STING Pathway.” J. Virol. 92 (2018): e01913-17. PubMed: 29263267.
|
|
Citation:
|
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: O’nyong-nyong Virus, UgMP 30, NR-51661.”
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|